All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Long-term outcomes of inotuzumab ozogamicin plus allo-HSCT conditioning regimen in CD22+ lymphoid malignancies

Feb 5, 2024
Learning objective: After reading this article, learners will be able to describe the effect of InO combined with allo-HSCT conditioning regiments on survival outcomes in lymphoid malignancies

Inotuzumab ozogamicin (InO) is an anti-CD22 monoclonal antibody that has demonstrated anti-tumor activity and manageable safety in patients with B-cell acute lymphoblastic leukemia (ALL) and lymphoma; however, it is associated with veno-occlusive disease, particularly in patients undergoing allogeneic stem cell transplantation (allo-SCT) receiving two-alkylating agent conditioning regimen or those with an elevated bilirubin level at or above the upper limit of normal pre-SCT.1

Here, we summarize a presentation by Khouri from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, on the long-term survival results of InO plus an allo-HSCT conditioning regimen in patients with relapsed/refractory CD22+ lymphoid malignancies.

Study methods

This study included patients aged 18–70 years with relapsed/refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma (NHL) who had an Eastern Cooperative Oncology Group Performance Status of ≤2, serum bilirubin <2 mg/dL, and alanine transaminase (AST) <2 times the upper limit of normal.

InO was given on Day 13 prior to the one-alkylator containing conditioning regimen of bendamustine/fludarabine/rituximab (BFR). Patients received tacrolimus and methotrexate for graft-versus-host disease (GvHD) prophylaxis.


In total, 26 patients were included in the study; baseline characteristics are summarized in Table 1.

Table 1. Baseline characteristics*

Characteristic, % (unless otherwise stated)

(N = 26)

Median age (range), years

59 (26–70)

              ≥60 years














Median prior lines of therapies (range), n

2.5 (1−6)

Prior autologous transplant


Prior therapies










              CAR T cell


Disease status at transplant








InO dose level


              0.6 mg/m2


              1.2 mg/m2


              1.86 mg/m2


Donor type






BFR, bendamustine, fludarabine, rituximab; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HCT-CI, hematopoietic cell transplantation – comorbidity index; InO, inotuzumab ozogamicin; MCL, mantle cell lymphoma; MUD, matched unrelated donor; MSD, matched sibling donor; PR, partial response; SD, stable disease.
*Data from Khouri.1

Graft-versus-host disease, treatment-related mortality, and response rates

Overall, 42% of patients did not have an absolute neutrophil count of <0.5 × 109/L, and 77% did not have a platelet count of <20 × 109/L. All patients had donor cell engraftment, with a median absolute neutrophil count recovery of 6.5 days and a median platelet recovery of 0 days.

Grade 2–4 acute GvHD occurred in 27% of patients, with Grade 3–4 in only 4%. The incidence of chronic GvHD was 50%. The 1- and 5-year treatment-related mortality was 12%.

Of the seven patients with chronic lymphocytic leukemia who had a partial response and stable disease at study entry, six achieved a CR post-allo-HSCT, with four patients achieving MRD-negativity. Among the four patients with CR at the time of transplant, three attained MRD negativity.

Survival and toxicities

At the median follow-up of 48.7 months, the 5-year overall survival (OS) and progression-free survival (PFS) were 84% and 80%, respectively. For patients receiving matched sibling donors (MSD) vs those with matched unrelated donors, the OS was 100% vs 72%, respectively; and the PFS was 100% vs 64%, respectively. There was a total of four deaths in study, due to acute GvHD (n = 2), cGvHD (n = 1), and progressive disease (n = 1).

Comparison analysis

For the comparison analysis between the BFR + InO study group and the historical control group (N = 56), there were no differences in the patient characteristics. Overall, there was a trend towards a better OS and PFS for patients with CD22+ NHL in the study vs the control group (Figure 1).

There was one case of veno-occlusive disease reported in the study group. Grade 1 AST increase was seen in nine patients within the control group and one patient in the study group; and Grade 2 AST increase was seen in one patient in each of the control and study group. Grade 1 and 2 bilirubin increase occurred in five and two patients, respectively, within the control group; and one patient each experienced Grade 1, 2, and 3 bilirubin increase in the study group.

Figure 1. 5-year OS and PFS in the study vs control group*  

OS, overall survival; PFS, progression-free survival.
*Adapted from Khouri.1

Presenter’s conclusion

This study showed that InO combined with BFR is a safe regimen that may improve survival outcomes for patients with CD22+ NHL; however, these data need to be validated in a larger cohort. Additional studies are ongoing investigating the efficacy and safety of InO with posttransplant cyclophosphamide to reduce the risk of GvHD in patients with CD22+ diseases, such as those with ALL undergoing HSCT.

  1. Khouri I. Addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation (allo-SCT) for relapsed CD22 (+) lymphoid malignancies: long-term survival results. Oral abstract #233. 65th American Society of Hematology Annual Meeting and Exposition; Dec 9, 2023; San Diego, US.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox